Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Grancalcin is a cytosolic, calcium-binding protein highly expressed in neutrophils and macrophages, belonging to the penta-EF-hand (PEF) family of proteins[1][2][3][5]. It contains five EF-hand motifs and is involved primarily in calcium-dependent cellular processes, possibly including neutrophil adhesion, migration, and granule-membrane fusion[1][2][3][5]. Its localization within cells depends on the presence of calcium and magnesium: in absence of divalent cations, it is cytosolic, but it associates with granule and membrane fractions under certain cationic conditions[3]. There is currently no evidence that grancalcin is a drug target, biomarker, or associated with specific disease mechanisms in humans, and there are no clinically relevant drugs or established safety concerns related to its targeting[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Grancalcin (GCA).